Walleye Capital
ANRO icon

Walleye Capital’s Alto Neuroscience ANRO Stock Holding History

Walleye Capital’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50,000
Closed -$768K – 6086
2024
Q1 		$768K Buy
+50,000
New +$783K ﹤0.01% 2836

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Walleye Capital's ANRO Position: Q2 2024 in Review

Walleye Capital sold out of Alto Neuroscience (ANRO) in Q2 2024, closing a stake of 50,000 shares — an estimated $768K sold.

Walleye Capital first reported a position in ANRO in Q1 2024 and held it in 1 quarter. The position peaked at $768K in Q1 2024. 58 funds tracked by Wall St. Rank hold ANRO as of Q2 2024.

  • Walleye Capital reported no remaining Alto Neuroscience position as of Q2 2024 after selling out during the quarter.
  • Walleye Capital sold 50,000 Alto Neuroscience shares in Q2 2024, an estimated $768K.
  • Walleye Capital first reported a position in Alto Neuroscience in Q1 2024 and held it in 1 quarter.
  • Walleye Capital's Alto Neuroscience position peaked at $768K in Q1 2024.
  • 58 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2024.

Based on Walleye Capital's 13F filing for Q2 2024, filed 14 Aug 2024.